Fabletics: Number One Activewear Brand for Common People

It’s hard to succeed in fashion these days. There are so many people trying to cash in on the e-commerce craze. Anyone can make their own products and sell them online. Even worse, big companies like Amazon have cornered the e-commerce markets across several industries.

In particular, Amazon controls 20 percent of the fashion e-commerce market. That other 80 percent is divided by the thousands upon thousands of other fashion companies. Somehow, despite the dominance of Amazon, Kate Hudson’s Fabletics found a way to succeed in fashion. Part of the ‘activewear’ movement, Fabletics is taking advantage of the millennial-inspired fashion trends.

In just over four years, Kate Hudson grew Fabletics into a $250 million business. Millennials love staying healthy and working out, but they also love relaxing. Activewear is the combination of those two loves. Fabletics perfectly combined aspirational designs with convenience; equaling simple success.

Fabletics is one of the high-value brands that common people can afford. Unlike other high-value brands, Fabletics doesn’t cost $100 for a pair of leggings. It’s also not poorly manufactured with cheap materials that break down over a few weeks. Fabletics took advantage of what is considered high-value these days.

Originally, high-value brands were fairly priced and made of good quality. That’s all any company needed to be successful; good prices and a good product or service. These days so much more goes into what’s considered a high-value brand. Consumers care more about things like customer experience, brand recognition, exclusive designs or deals, and last-mile service.

As Fabletics grew, the company decided to expand into the real world. Currently, there are 16 physical Fabletics stores. Although the plan is to open more stores, Fabletics had to discuss a serious issue before it can.

A lot of retail stores are “getting killed” by “showrooming”. People shop around in their stores and then buy those same items somewhere else cheaper. To counter that trend, Fabletics invites the local markets into their stores during events and other activities. As a result, nearly one-fourth of new visitors become members in store.

One Fabletics reviewer talked about Fabletic’s good quality and prices. Fabletics can easily compare and outperform other high-value brands like Lululemon. If anyone’s interested in Fabletics, they can take the Fabletics LifeStyle Quiz and see the products they’d be matched with.

Under Siegall’s leadership, Seattle Genetics devises ingenious products

Seattle Genetics is perhaps best known for the development of the first FDA-approved antibody drug conjugate, ADCetris. This highly innovative drug has been FDA-approved for the treatment of refractory non-Hodgkin’s lymphoma disease, a major killer in the United States, affecting more than half a million people at any given time. This drug has made serious dent in the mortality rates for this difficult to treat illness, saving thousands of lives and making Seattle Genetics a small fortune in the process.

But Seattle Genetics, like all pharmaceutical companies, has needed to heavily diversify its revenue streams. This is a result of the nature of the pharmaceutical business. Companies are often forced to fund study after study and project after project in the mad race to get a drug FDA approved. For every 10 drugs that are initially put into phase one clinical trials, only one will ultimately be FDA-approved. The other nine drugs are all costs that are born directly by the pharmaceutical company developing them. This results in an extremely expensive process, requiring massive amounts of capital and making pharmaceutical companies one of the most capital-intensive and risky businesses in the world today.

For this reason, Seattle Genetics has diversified its revenue into licensing both products and the manufacture of other drugs. They also license out patented processes, by which other companies can perform the same kinds of highly innovative research that Seattle Genetics has been able to do and that has ultimately led them to having the first FDA-approved antibody drug conjugate.

Among these patented processes is Seattle Genetics’ highly innovative means for the production of monoclonal antibodies, which are used in the creation of antibody drug conjugates. First, a rat is injected with malignant cells. The rat’s body then actually produces antibodies in response to the presence of these foreign tissues. Those antibodies are then isolated in a laboratory. Every molecule resembling those antibodies is in synthetically produced, sometimes creating thousands or even tens of thousands of individual molecules. These molecules are then tested on animals and human subjects, in order to see which ones yield the lowest incidence of serious side effects, while still retaining the ability to target the specified malignancy.